Christine Shaw, VP, Assay Development at GenMark Diagnostics, Inc. (GNMK), sold 68 shares at $11.34 ($771) on 2020-10-27, disclosed to the SEC on 2020-10-29.
Open-market sale of $771 GNMK by VP, Assay Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| GNMK | SELL | 2021-02-25 | $8K | — | Filing → |
| GNMK | SELL | 2021-01-29 | $1K | — | Filing → |
| GNMK | SELL | 2020-12-09 | $4K | — | Filing → |